Alfasigma
As of the edition of 20 October 2026, Alfasigma runs 10 drugs, 5 of them marketed; it is on route A at 0 targets and on route B at 2 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 4 company names in this family.
- Intercept Pharmaceuticals: acquired in 2023
- SOFAR S.p.A.: acquired in 2023; successor Alfasigma S.p.A.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 2 |
| Withdrawn from market | 1 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Filgotinib | none listed | 3 |
| Obeticholic acid | Ends 2033 (patent) | 1 |
| Piperaquine | none listed | 0 |
| Artenimol | none listed | 0 |
| Linerixibat | Ends 2033 (exclusivity) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 2 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Alfasigma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Digestive system: 15 trials led
- Immune system: 3 trials led
- Blood and lymph: 1 trials led